Pembrolizumab-Induced Retroperitoneal Fibrosis Detected on 68 Ga-FAPi PET/CT.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40916107.
- Also identified by DOI 10.1097/RLU.0000000000006130.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide. Immune checkpoint inhibitors (ICI) have improved progression and overall survival in patients progressing on sorafenib therapy. But activation of the immune system can lead to numerous immune-related adverse events. Here we present a case of hepatocellular carcinoma with abdominal pain after initiation of pembrolizumab. 68 Ga-FAPi PET/CT highlighted FAPi avid soft tissue density in the paraaortic and presacral regions with diffusely increased FAPi uptake in the thyroid, suggestive of ICI-induced retroperitoneal fibrosis and thyroiditis.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Retroperitoneal Fibrosis
- Antibodies, Monoclonal, Humanized